Effect of Two or Six Doses 800 mg of Albendazole Every Two Months on Loa loa Microfilaraemia: A Double Blind, Randomized, Placebo-Controlled Trial

• Published in: PLoS neglected tropical diseases Vol. 10; no. 3; p. e0004492
• Main Authors: Kamgno, Joseph, Nguipdop-Djomo, Patrick, Gounoue, Raceline, Téjiokem, Mathurin, Kuesel, Annette C.
• Format: Journal Article
• Language: English
• Published: United States Public Library of Science 11.03.2016; Public Library of Science (PLoS)
• Subjects: Adolescent; Adult; Aged; Albendazole; Albendazole - administration & dosage; Albendazole - adverse effects; Analysis; Anthelmintics - administration & dosage; Anthelmintics - adverse effects; Biology and Life Sciences; Cameroon; Care and treatment; Communicable diseases; Disease; Dosage and administration; Double-Blind Method; Drug dosages; Female; Humans; Loiasis - drug therapy; Male; Medicine and Health Sciences; Middle Aged; Placebos - administration & dosage; Research and Analysis Methods; Studies; Treatment Outcome; Tropical diseases; Young Adult; Cameroon; Africa
• ISSN: 1935-2735; 1935-2727; 1935-2735
• DOI: 10.1371/journal.pntd.0004492

Loiasis is a parasitic infection endemic in the African rain forest caused by the filarial nematode Loa loa. Loiasis can be co-endemic with onchocerciasis and/or lymphatic filariasis. Ivermectin, the drug used in the control of these diseases, can induce serious adverse reactions in patients with high L loa microfilaraemia (LLM). A drug is needed which can lower LLM below the level that represents a risk so that ivermectin mass treatment to support onchocerciasis and lymphatic filariasis elimination can be implemented safely. Sixty men and women from a loiasis endemic area in Cameroon were randomized after stratification by screening LLM (≤ 30000, 30001-50000, >50000) to three treatment arms: two doses albendazole followed by 4 doses matching placebo (n = 20), six doses albendazole (n = 20) albendazole or 6 doses matching placebo (n = 20) administered every two months. LLM was measured before each treatment and 14, 18, 21 and 24 months after the first treatment. Monitoring for adverse events occurred three and seven days as well as 2 months after each treatment. None of the adverse events recorded were considered treatment related. The percentages of participants with ≥ 50% decrease in LLM from pre-treatment for ≥ 4 months were 53%, 17% and 11% in the 6-dose, 2-dose and placebo treatment arms, respectively. The difference between the 6-dose and the placebo arm was significant (p = 0.01). The percentages of participants with LLM < 8100 mf/ml for ≥ 4 months were 21%, 11% and 0% in the 6-dose, 2-dose and placebo treatment arms, respectively. The 6-dose regimen reduced LLM significantly, but the reduction was insufficient to eliminate the risk of severe and/or serious adverse reactions during ivermectin mass drug administration in loiasis co-endemic areas.